|
See related Faslodex inj[法洛德 注射劑] information |
|
|
|
製造商 |
AstraZeneca |
|
代理/經銷商 |
AstraZeneca |
|
成份 |
Fulvestrant |
|
適應症 |
Treatment of postmenopausal women of any age with locally advanced or metastatic breast cancer who have been previously treated with endocrine therapy. |
|
用量 |
Adult females (including the elderly) 500 mg slow IM into the buttock at intervals of 1 month, with an additional 500 mg dose given two weeks after the initial dose. |
|
過量 |
View Faslodex[法洛德] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
[Click for Faslodex[法洛德] detailed prescribing infomation] |
|
注意事項 |
Moderate to severe hepatic impairment; creatinine clearance < 30 mL/min; bleeding diatheses or thrombocytopenia, or patients on anticoagulants; pregnancy & lactation. |
|
不良反應 |
Inj site reactions, hot flushes, headache, asthenia, nausea & other GI disturbances, rash, UTI.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Faslodex[法洛德] detailed prescribing infomation]
View more drug interactions with Faslodex[法洛德] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Faslodex[法洛德] detailed prescribing infomation |
|
儲存 |
View Faslodex[法洛德] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Faslodex[法洛德] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Faslodex[法洛德] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Faslodex 注射劑 |
|
Faslodex (Pre-filled syringe) 250 mg/5 mL x 1's |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
AstraZeneca |
|
|
|
|
